Containment Generic Pharmaceutical Marketing Production 
The Pharma Data
MARCH 15, 2022
Agency Supports Development of Complex Generic Drug-Device Combination Product to Improve Competition and Access to More Affordable Medicines. This complex generic drug-device combination product, which is a metered-dose inhaler, should not be used to treat acute asthma attacks. Today, the U.S.
The Pharma Data
MAY 8, 2021
The Sandoz division has a leading global portfolio with eight marketed biosimilars and a further 15-plus in various stages of development. Eylea ® is a trademark of Bayer AG and in the US of Regeneron Pharmaceuticals, Inc. Nor can there be any guarantee that such products will be commercially successful in the future.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
MAY 18, 2021
Kundl, Austria further strengthens production for oral antibiotics while facility in Palafolls, Spain expands for sterile active pharmaceutical ingredients. As part of this network modernization plan, Sandoz will phase out the current production of oral APIs at the Les Franqueses site in Spain, which it plans to close in 2024.
The Pharma Data
MAY 2, 2021
With eight marketed biosimilar medicines globally and 15+ molecules in pipeline, Sandoz is investing in future of biosimilars for patients and healthcare systems. The Sandoz division has a leading global portfolio with eight marketed biosimilars and a further 15-plus in various stages of development. Disclaimer.
The Pharma Data
MAY 15, 2023
Before joining EMMI Group as CEO, he was a Member of the Executive Board and Head of the Marketing Department at Migros-Genossenschafts-Bund. He holds a Master degree in Marketing and Trade from the University of St. Nor can there be any guarantee that such products will be commercially successful in the future.
Pharma in Brief
DECEMBER 3, 2023
The Regulations were meant to counterbalance the early-working exception by providing innovators with an enforcement tool to prevent patent infringement prior to generic or biosimilar market entry. These provisions were further amended in 2015 to clarify the level of product specificity required for combination drugs and formulations.
XTalks
AUGUST 2, 2023
We delve into the driving forces behind their successes and shed light on the groundbreaking research that has earned them a place among the elite in the pharmaceutical arena. is a global pharmaceutical company, working across both developed and emerging markets. It contains the antiviral medications nirmatrelvir and ritonavir.
Expert insights. Personalized for you.
52 
Let's personalize your content